Compare NVST & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVST | GRFS |
|---|---|---|
| Founded | 2018 | 1940 |
| Country | United States | Spain |
| Employees | N/A | 25247 |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.9B |
| IPO Year | 2019 | N/A |
| Metric | NVST | GRFS |
|---|---|---|
| Price | $26.69 | $7.26 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 13 | 2 |
| Target Price | ★ $26.46 | $10.15 |
| AVG Volume (30 Days) | ★ 2.6M | 701.4K |
| Earning Date | 05-06-2026 | 07-28-2022 |
| Dividend Yield | N/A | ★ 1.80% |
| EPS Growth | ★ 104.31 | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $2,566,500,000.00 | N/A |
| Revenue This Year | $6.67 | $4.49 |
| Revenue Next Year | $3.55 | $6.42 |
| P/E Ratio | $117.46 | ★ $18.67 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $18.77 | $6.96 |
| 52 Week High | $30.42 | $11.14 |
| Indicator | NVST | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 56.02 | 46.95 |
| Support Level | $22.31 | $6.96 |
| Resistance Level | $28.22 | $7.73 |
| Average True Range (ATR) | 0.82 | 0.17 |
| MACD | -0.06 | 0.03 |
| Stochastic Oscillator | 52.61 | 64.89 |
Envista Holdings Corp is a dental products company. It develops, manufactures, and markets portfolios of dental consumables, equipment, and services to dental professionals. The company's business consists of two segments; Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment, which derives key revenue, develops, manufactures, and markets dental implant systems, including regenerative solutions, dental prosthetics, and associated treatment software and technologies, as well as orthodontic bracket systems, aligners, and lab products. Geographically, the company generates a majority of its revenue from North America, followed by Western Europe and other developed and emerging markets.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.